Core Viewpoint - Mangoceuticals, Inc. has launched two weight-management programs, MangoRx Direct and PeachesRx Direct, allowing patients to access FDA-approved GLP-1 medications from Eli Lilly and Novo Nordisk through its platform [2][4]. Group 1: Program Details - The MangoRx Direct and PeachesRx Direct programs are licensed to issue valid prescriptions for GLP-1 medications, including Zepbound and Wegovy, through a third-party provider [2][5]. - Patients can fill prescriptions at any licensed pharmacy, with the medical operations and prescribing providers vetted by an independent third-party provider [3][5]. - The programs offer telehealth consultations, personalized care plans, and ongoing support for a monthly fee of $99, excluding medication costs [6]. Group 2: Company Overview - MangoRx focuses on men's health and wellness products via a secure telemedicine platform, targeting areas such as erectile dysfunction, hair growth, hormone replacement therapies, and weight management [7]. - The company aims to provide a smooth telemedicine experience, with prescription requests reviewed by physicians and fulfilled through partner pharmacies [7].

美国远程医疗平台Mangoceuticals(MGRX.US)周四盘前股价飙升约19%，此前公司宣布与制药巨头礼来 (LLY.US)和诺和诺德(NVO.US)达成合作协议，将为用户直接提供两大药企的明星GLP-1减重药物。 总部位于美国德州达拉斯的Mangoceuticals表示，公司已推出MangoRx Direct和PeachesRx Direct平台， 面向自费用户销售礼来的Zepbound(替尔泊肽)以及诺和诺德的Wegovy(司美格鲁肽)。 ...

总部位于美国德州达拉斯的Mangoceuticals表示，公司已推出MangoRx Direct和PeachesRx Direct平台， 面向自费用户销售礼来的 Zepbound(替尔泊肽)以及诺和诺德的Wegovy(司美格鲁肽)。 智通财经APP获悉，美国远程医疗平台Mangoceuticals(MGRX.US)周四盘前股价飙升约19%，此前公司 宣布与制药巨头礼来(LLY.US)和诺和诺德(NVO.US)达成合作协议，将为用户直接提供两大药企的明星 GLP-1减重药物。 ...